Twist Bioscience Financial Statements
NASDAQ: TWSTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Twist Bioscience revenue and earnings
In fiscal 2025, Twist Bioscience generated $376.6 million in revenue, up 20.3% from fiscal 2024, its 8th consecutive year of revenue growth. Twist Bioscience reported a net loss of $77.7 million, compared with a loss of $208.7 million a year earlier. Gross margin was 50.7% (up from 42.6%) and operating margin -36.2%.
Diluted earnings per share came in at -$1.30. Over the last 5 fiscal years, TWST's revenue has grown at a 33.1% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Twist Bioscience income statement (annual)
| Fiscal year (USD) | FY 20252025-09-30 | FY 20242024-09-30 | FY 20232023-09-30 | FY 20222022-09-30 | FY 20212021-09-30 | FY 20202020-09-30 | FY 20192019-09-30 | FY 20182018-09-30 | FY 20172017-09-30 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 376.57M | 312.97M | 245.11M | 203.56M | 132.33M | 90.10M | 54.38M | 25.43M | 10.77M |
| Revenue growth (YoY) | +20.32% | +27.69% | +20.41% | +53.83% | +46.87% | +65.67% | +113.89% | +136.16% | — |
| Cost of Revenue | 185.57M | 179.63M | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M | 32.19M | 24.02M |
| Gross Profit | 191.00M | 133.35M | 89.73M | 84.23M | 51.71M | 28.69M | 6.96M | -6.76M | -13.25M |
| Operating Expenses | 327.26M | 354.18M | 306.89M | 319.01M | 204.44M | 168.77M | 115.81M | 63.80M | 45.23M |
| Research & Development | 80.28M | 90.85M | 106.89M | 120.31M | 69.07M | 43.01M | 35.68M | 20.35M | 19.17M |
| Selling, General & Admin | 246.98M | 218.40M | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M | 43.45M | 26.06M |
| Operating Income | -136.26M | -220.83M | -217.16M | -234.78M | -152.73M | -140.08M | -108.85M | -70.56M | -58.48M |
| Interest Expense | — | 29.00K | 5.00K | 80.00K | 367.00K | 787.00K | 1.29M | 1.31M | 905.00K |
| Other Income (Expense) | -903.00K | -2.68M | -672.00K | -1.09M | -1.37M | -182.00K | -265.00K | -121.00K | -55.00K |
| Pretax Income | -76.95M | -208.17M | -203.47M | -228.27M | -154.03M | -139.55M | -107.38M | -70.99M | -59.03M |
| Income Tax | 719.00K | 560.00K | 1.15M | -10.41M | -1.93M | 382.00K | 292.00K | 242.00K | 280.00K |
| Net Income | -77.67M | -208.73M | -204.62M | -217.86M | -152.10M | -139.93M | -107.67M | -71.24M | -59.31M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -25.51 | -24.49 |
| EPS (Diluted) | -1.30 | -3.60 | -3.60 | -4.04 | -3.15 | -3.57 | -3.92 | -25.51 | -24.49 |
| Shares Outstanding (Basic) | 59.81M | 58.02M | 56.88M | 53.88M | 48.25M | 39.19M | 27.46M | 2.79K | 2.42B |
| Shares Outstanding (Diluted) | 59.81M | 58.02M | 56.88M | 53.88M | 48.25M | 39.19M | 27.46M | 2.79K | 2.42B |
| EBITDA | -111.41M | -189.40M | -187.85M | -218.26M | -142.98M | -133.40M | -102.74M | -64.83M | -53.46M |
| Gross Margin | 50.72% | 42.61% | 36.61% | 41.38% | 39.08% | 31.85% | 12.80% | -26.59% | -123.09% |
| Operating Margin | -36.18% | -70.56% | -88.60% | -115.33% | -115.41% | -155.47% | -200.15% | -277.50% | -543.16% |
| Net Margin | -20.63% | -66.69% | -83.48% | -107.02% | -114.94% | -155.31% | -197.98% | -280.16% | -550.85% |
This table shows 9 annual periods of Twist Bioscience's income statement, from FY 2025 back to FY 2017, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow TWST's reporting calendar. What is a income statement?